Nebraska hemp industry faces uncertain future
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyHempTHCIndustrySafetyCBDDosing Why This Matters Clinicians need to understand that regulatory uncertainty in…
Medical Cannabis and Anxiety in 2026: What Patients Need to Know Before Treatment
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. AnxietyMental HealthResearchSafetyCBDTHCDosing Why This Matters Clinicians need current evidence on cannabis efficacy and…
Medicinal Cannabis Matters: Friday Roundup – 19 June 2026
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PainAnxietyMental HealthResearchPolicySafetyDosing Dr. Caplan’s Take I appreciate patient narratives, but a single…
CBD and Cardiovascular Recovery: HRV, Blood Pressure – Dr. Damas Cannabis
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CBDResearchSafetyAnxietyAgingDosingPolicy Why This Matters Clinicians should be cautious about recommending CBD for…
Summer Bud Guide
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. IndustryTHCCBDSafetyDosingResearchPolicy Why This Matters Clinicians should understand that patients increasingly make…
Clinical Trial: High Doses of CBD Superior to Placebo in Treating Neuropathic Pain
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CBDPainResearchNeurologyDosingSafetyPolicy Why This Matters This trial provides clinicians with evidence-based dosing…
PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthSafetyCBDDosingHempIndustry Why This Matters This Phase 3 trial represents progress toward a…
Cannabis Warning Label Regulations and Characteristics in US States with Medical and …
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyDosingMental HealthPediatricsTHC Why This Matters Clinicians need standardized, evidence-based…
Guest columnist: Washington should ensure stable hemp market | State-Journal
✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyHempCBDIndustrySafetyResearchDosing Why This Matters Clinicians prescribing or recommending hemp-derived…
PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthCBDSafetyDosingIndustryHemp Why This Matters Clinicians currently lack FDA-approved pharmacotherapy…